Aliphatic spirolactam CGRP receptor antagonists

US9227972B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9227972-B2
Application numberUS-201314399649-A
CountryUS
Kind codeB2
Filing dateMay 3, 2013
Priority dateMay 9, 2012
Publication dateJan 5, 2016
Grant dateJan 5, 2016

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The present invention is directed to aliphatic spirolactam derivatives which are antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which CGRP is involved, such as migraine. The invention is also directed to pharmaceutical\compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

First claim

Opening claim text (preview).

What is claimed is: 1. A compound which is: (3′S)-3-(3-(6-Methyl-2-oxo-1-(2,2,2-trifluoroethyl)-5-(2,3,5-trifluorophenyl)piperidin-3-yl)prop-1-en-1-yl)-5,7-dihydrospiro[cyclopenta[b]pyridine-6,3′-pyrrolo[2,3-b]pyridin]-2′(1′H)-one; or a pharmaceutically acceptable salt thereof. 2. A compound of the Formula: wherein, “nR A ” is from 0 to 4 halogen substituents and R B and R C are independently C 1-6 -alkyl which are optionally substituted with halogen. 3. A pharmaceutical composition comprising a compound of claim 2 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. 4. A method of treating Migraine by providing an effective amount of a pharmaceutical formulation of claim 3 to a patient in need thereof.

Assignees

Inventors

Classifications

  • Antimigraine agents · CPC title

  • having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine · CPC title

  • having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide · CPC title

  • containing further heterocyclic ring systems · CPC title

  • C07D471/20Primary

    Spiro-condensed systems · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9227972B2 cover?
The present invention is directed to aliphatic spirolactam derivatives which are antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which CGRP is involved, such as migraine. The invention is also directed to pharmaceutical\compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in…
Who is the assignee on this patent?
Merck Sharp & Dohme
What technology area does this patent fall under?
Primary CPC classification C07D471/20. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Jan 05 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).